Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
Sequences from 82 protease inhibitors (PI)-experienced patients were analysed for the presence of previously described in-vitro resistance mutations to PA-457 located in the C-terminal capside (H226Y, L231F, L231M) and in the N-terminal SP1 (A1V, A3T, A3V) within the CA-SP1 boundary domain. Overall, the CA-SP1 cleavage site was highly conserved in PI pre-treated patients and only one patient showed an L231M mutation. The impact of this mutation should be further addressed in vivo.
Malet
Isabelle
I
Laboratoire de Virologie, Université Pierre et Marie Curie (Paris 6), France.
Wirden
Marc
M
Derache
Anne
A
Simon
Anne
A
Katlama
Christine
C
Calvez
Vincent
V
Marcelin
Anne-Geneviève
AG
D000595:Amino Acid Sequence; D019380:Anti-HIV Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral / Q000235:genetics*; D015683:Gene Products, gag / Q000235:genetics; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D013386:Succinates / Q000494:pharmacology*; D014315:Triterpenes / Q000494:pharmacology*; D054301:gag Gene Products, Human Immunodeficiency Virus; D053978:Pentacyclic Triterpenes
D019380:Anti-HIV Agents; D015683:Gene Products, gag; D017320:HIV Protease Inhibitors; D013386:Succinates; D014315:Triterpenes; D054301:gag Gene Products, Human Immunodeficiency Virus; C059827:HIV gag protein p25; C479935:bevirimat; D053978:Pentacyclic Triterpenes